Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.

Blood cancer journal - 2 Jan 2015

Patnaik M M, Wassie E A, Padron E, Onida F, Itzykson R, Lasho T L, Kosmider O, Finke C M, Hanson C A, Ketterling R P, Komrokji R, Tefferi A, Solary E

Abstract excerpt

In patients with chronic myelomonocytic leukemia (CMML), age>65 years is an adverse prognostic factor. Our objective in the current study was to examine risk factors for survival and treatment outcome in 261 'young' adults with CMML, as defined by age ⩽65 years. In multivariable analysis, lower H...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to Leukemia, Myelomonocytic, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nuclear Proteins

Share to Prognosis

Share to Ribonucleoproteins

Share to Serine-Arginine Splicing Factors

Share to Treatment Outcome

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 25555161
DOI: 10.1038/bcj.2014.90
PMCID: PMC5404217

Genes

ASXL1
SRSF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25555161-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.PMID 25555161Read ↗

Novel therapeutic targets for chronic myelomonocytic leukemia.Semantic proximity Read ↗

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.Semantic proximity Read ↗

Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.Semantic proximity Read ↗

Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.Semantic proximity Read ↗

Emerging drugs for the treatment of chronic myelomonocytic leukemia.Semantic proximity Read ↗

[Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].Semantic proximity Read ↗

Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?Semantic proximity Read ↗

Prognostic score including gene mutations in chronic myelomonocytic leukemia.Semantic proximity Read ↗

Therapy related‐chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMMLSemantic proximity Read ↗

DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia.Semantic proximity Read ↗

Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.